Ayahuasca Therapy Guide: What to Know Before You Go

Interest in ayahuasca has grown steadily over the past decade. Documentaries, podcasts, and word of mouth have turned what was once an obscure Amazonian ceremony into a global wellness trend, with seekers traveling from North America and Europe to Peru, Brazil, and Colombia in search of healing, clarity, or insight. Some report profound, lasting shifts. Some report the worst nights of their lives. Many report both.

What gets lost in most conversations about ayahuasca is the specificity of its risks, particularly for people with certain health histories. This guide is not here to tell you whether ayahuasca is right for you. It is here to give you the grounded, clinical picture so that if you are considering it, you are doing so with accurate information rather than retreat marketing copy.

What Ayahuasca Actually Is

Ayahuasca is a brew made from two plants: the Banisteriopsis caapi vine and the leaves of Psychotria viridis (also called chacruna). Neither plant produces significant psychoactive effects alone. Together, they create something pharmacologically distinct from other psychedelics.

The chacruna leaves contain N,N-dimethyltryptamine (DMT), a potent serotonergic compound. Ordinarily, DMT is broken down almost immediately by monoamine oxidase (MAO) enzymes in the gut and liver before it can reach the brain. The caapi vine contains beta-carboline alkaloids, specifically harmine, harmaline, and tetrahydroharmine, which act as reversible inhibitors of MAO-A. By temporarily blocking those enzymes, the vine allows DMT to survive digestion and cross into the central nervous system, where it activates serotonin receptors, primarily 5-HT2A.

This MAOI mechanism is the key to understanding ayahuasca’s safety profile and its contraindications. It is also what makes it pharmacologically different from psilocybin or LSD, which do not carry the same drug interaction risks.

Effects typically begin within 30 to 60 minutes of drinking the brew and last four to six hours. They include intense visual and auditory experiences, altered time perception, emotional amplification, and a strong physical purge in the majority of participants. Vomiting and diarrhea are considered part of the ceremony by many traditions, but they also carry real physiological consequences in people who are dehydrated or medically fragile.

What the Research Shows (and What It Does Not)

There is a growing body of clinical research on ayahuasca and depression. A randomized placebo-controlled trial published in Psychological Medicine found significant antidepressant effects in patients with treatment-resistant major depression seven days after a single dosing session, with a between-group effect size (Cohen’s d = 1.49) comparable to ketamine trials. That is a meaningful signal, though it comes from a small trial (35 participants) conducted in a controlled hospital setting with professional supervision, follow-up assessments, and immediate medical backup, not a jungle retreat with minimal screening.

A 2025 review in CNS Spectrums summarizing the pharmacology, safety, and therapeutic research noted that preclinical and early clinical data suggest antidepressant, anxiolytic, and neuroplastic benefits, with no evidence of dependence or significant tolerance. The same review noted that risks remain, including psychotic episodes and hazardous interactions with serotonergic medications.

Here is what the research does not show: that ayahuasca is safe in uncontrolled settings, that the benefits translate outside of supervised clinical or ceremonial contexts, or that the healing reported anecdotally from retreats reflects what clinical trials have actually measured. These are important distinctions: the research is promising and early, and the retreat industry is large and largely unregulated.

Ayahuasca Safety Risks: The Specific Picture

Ayahuasca safety risks fall into two broad categories: pharmacological and contextual. Both matter, and they interact.

On the pharmacological side, the MAOI activity of the beta-carboline alkaloids creates a specific and serious drug interaction risk. Combining ayahuasca with SSRIs, SNRIs, MAOIs, or other serotonergic medications can trigger serotonin syndrome, a condition characterized by agitation, tremors, hyperthermia, and in severe cases, seizure or death. This is a documented risk, not a theoretical one. Anyone taking antidepressants needs to understand this before considering ayahuasca, and stopping SSRIs abruptly to attend a retreat carries its own serious risks.

Cardiovascular effects are also consistent across studies. DMT and the beta-carbolines elevate heart rate and blood pressure during the session. For most healthy adults, these changes are transient and manageable. For people with cardiovascular disease, uncontrolled hypertension, or cardiac arrhythmias, they can be dangerous. A 2024 systematic thematic review of adverse events published in the Journal of Psychoactive Drugs flagged transient hypertension and, in one clinical case, significant bradycardia requiring intervention.

The purging itself carries risk for people with liver conditions, kidney problems, or severe gastrointestinal disorders. Dehydration and electrolyte imbalance from prolonged vomiting are real concerns, particularly in retreat settings without medical staff present.

On the psychological side, ayahuasca can precipitate or worsen psychotic episodes in people with a personal or family history of psychosis, schizophrenia, or bipolar disorder with psychotic features. The intensity of the experience can also be deeply destabilizing for people with unprocessed trauma, without adequate preparation and integration support in place beforehand.

For a comprehensive overview of who should and should not consider psychedelic experiences, see our guide to Contraindications for Psychedelic Therapy.

Who Should Not Use Ayahuasca

The contraindication list for ayahuasca is longer and more specific than for most other psychedelics, primarily because of the MAOI component. People who should not use ayahuasca include those currently taking SSRIs, SNRIs, MAOIs, tramadol, lithium, or other serotonergic medications; people with a personal or family history of schizophrenia, bipolar I disorder, or other psychotic conditions; people with uncontrolled hypertension or significant cardiovascular disease; people with serious liver or kidney conditions; and people who are pregnant or breastfeeding.

Diet also matters in the context of MAOI activity. Foods high in tyramine, including aged cheeses, cured meats, and fermented products, can interact with MAO inhibition and produce dangerous blood pressure spikes. Reputable retreat centers provide dietary guidelines to follow in the days before a ceremony. If a retreat is not providing these guidelines, that is a meaningful red flag about their screening standards overall.

Legal Status: A Complex Map

The legal picture for ayahuasca varies considerably depending on where you are. In the United States, DMT is classified as a Schedule I controlled substance under federal law, making ayahuasca illegal outside of specific religious exemptions held by groups such as the Uniao do Vegetal and Santo Daime. Some U.S. cities have decriminalized entheogenic plants locally, but commercial retreats remain legally prohibited, and participants outside religious exemptions carry real legal risk.

In Peru, ayahuasca has been legally protected as part of the country’s cultural heritage since 2008, and it is widely practiced by licensed facilitators. Brazil allows it for religious and indigenous use under frameworks established since the late 1980s. Colombia recognizes it under indigenous cultural protections. These are the primary countries where legal, structured retreat access exists with some cultural framework behind it.

In Europe, the picture is patchwork. Spain and Portugal are often described as having more permissive or ambiguous environments, while Germany, France, and the UK classify ayahuasca as illegal and enforce that classification. The Netherlands banned it in 2019 after previously operating in a gray zone. Even in countries where retreats operate openly, there is typically no formal regulation of retreat quality, screening standards, or facilitator qualifications.

This legal complexity matters for a specific reason: when something is legally unregulated, quality control is entirely dependent on the ethics and competence of individual operators. That is not a reason to avoid it categorically, but it is a reason to vet very carefully.

Why Set, Setting, and Support Matter Even More Here

The concept of set (mindset) and setting (physical and social environment) applies to all psychedelic experiences. With ayahuasca, the stakes around both are higher than with most other substances, and support extends beyond the ceremony itself.

Set matters because ayahuasca tends to amplify whatever psychological material a person brings into the experience. People who enter a ceremony carrying unprocessed grief, unresolved trauma, or significant psychological instability without having worked through adequate preparation are not protected from difficulty by the substance itself. Preparation is not a formality; it is what makes the difference between entering an experience with a foundation and entering it without one.

Setting matters because the physical environment, the facilitator’s competence, the screening protocols, and the presence or absence of medical backup all shape what happens when something goes wrong. At a well-run retreat, a participant experiencing cardiac distress has a pathway to care. At an unvetted operation in an unregulated legal context, they may not.

Support, in the integration phase that follows the ceremony, is where the clinical research suggests a significant portion of lasting benefit either takes root or does not. An intense experience without a container for making sense of it is not the same as a guided process. This is where working with a professional, whether a trained integration therapist or a concierge service that provides continuity of care through preparation, the experience, and afterward, changes the outcome profile substantially.

The ayahuasca retreat industry has grown faster than its safety infrastructure. That gap is where seekers are most vulnerable, and where informed preparation makes the largest difference.

How to Approach This Decision

If you are considering an ayahuasca experience, start with an honest accounting of your medical and psychiatric history. Review the contraindications with someone who knows your full medication list and health background. Ask potential retreat centers specific questions: What is your screening process? Do you have medical staff on site or on call? What dietary and medication protocols do you require? What integration support do you offer afterward?

If the answers are vague, or if the retreat is more focused on selling you the transformation than helping you assess whether it is appropriate for you, that tells you something important.

The research on ayahuasca therapy is real and it is growing. So is the retreat tourism industry, and the two are not the same thing. Approaching this with the same rigor you would apply to any significant medical decision is not overcautious. It is appropriate to what is actually at stake.